Jens Matuszczyk

Jens Matuszczyk

Auto-generated profile, based on publicly available information

Jens Matuszczyk

Sartorius Stedim Biotech GmbH, Germany

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
27 November 2018 in Biotechnology Progress
Verified
Journal Article
Open access
PDF file
SJSabrina Janoschek
Sabrina Janoschek
MSMarkus Schulze
Markus Schulze
GZGerben Zijlstra
Gerben Zijlstra
GGGerhard Greller
Gerhard Greller
JMJens Matuszczyk
Jens Matuszczyk
Continuous processes such as perfusion processes can offer advantages compared to fed‐batch or batch processes in bio‐processing: improved product quality (e.g. for labile products), increased product yield, and cost savings. In this work, a semi‐perfusion process was established in shake flasks and transferred to an automated small‐scale bioreactor by daily media exchange via centrifugation based on an existing fed‐batch process platform. At first the development of a suitable medium and feed composition, the glucose concentration required by the cells and the cell‐specific perfusion rate were investigated in shake flasks as the conventional scale‐down system. This lead to an optimized process with a threefold higher titer of 10 g/L monoclonal antibody compared to the standard fed‐batch. To proof the suitability and benefit as a small‐scale model, the established semi‐perfusion process was transferred to an automated small‐scale bioreactor with improved pH and dissolved oxygen control. The average specific productivity improved from 24.16 pg/(c*d) in the fed‐batch process and 36.04 pg/c*d in the semi‐perfusion shake flask to 38.88 pg/(c*d) in the semi‐perfusion process performed in the controlled small‐scale bioreactor, thus illustrating the benefits resulting from the applied semi‐perfusion approach, especially in combination with controlled DO and pH settings. © 2019 The Authors. Biotechnology Progress published by Wiley Periodicals, Inc. on behalf of American Institute of Chemical Engineers Biotechnol. Prog ., 35: e2757, 2019.

4 June 2021 in Journal of Biotechnology
Verified
Journal Article
Open access
MSMarkus Schulze
Markus Schulze
JLJohannes Lemke
Johannes Lemke
DPDavid Pollard
David Pollard
RWRene H. Wijffels
Rene H. Wijffels
JMJens Matuszczyk
Jens Matuszczyk
DMDirk E. Martens
Dirk E. Martens
Current CHO cell production processes require an optimized space-time-yield. Process intensification can support achieving this by enhancing the productivity and improving facility utilization. The use of perfusion at the last stage of the seed train (N-1) for high cell density inoculation of the fed-batch N-stage production culture is a relatively new approach with few industry applicable examples. Within this work, the impact of the cell-specific perfusion rate (CSPR) of the N-1 perfusion and the relevance of its control for the quality of generated inoculation cells was evaluated using an automated perfusion rate (PR) control based on online biomass measurements. Precise correlations (R² = 0.99) between permittivity and viable cell counts were found up to the high densities of 100⋅106 c·mL−1. Cells from N-1 perfusion were cultivated at a high and low CSPR with 50 and 20 pL·(c·d)−1, respectively. Lowered cell growth and an increased apoptotic reaction was found as a consequence of the latter due to nutrient limitations and reduced uptake rates. Subsequently, batch cultivations (N-stage) from the different N-1 sources were inoculated to evaluate the physiological state of the inoculum. Successive responses resulting from the respective N-1 condition were uncovered. While cell growth and productivity of approaches inoculated from high CSPR and a conventional seed were comparable, low CSPR inoculation suffered significantly in terms of reduced initial cell growth and impaired viability. This study underlines the importance to determine the CSPR for the design and implementation of an N-1 perfusion process in order to achieve the desired performance at the crucial production stage.

20 September 2021 in Biotechnology Progress
Verified
Journal Article
Open access
PDF file
MSMarkus Schulze
Markus Schulze
JNJulia Niemann
Julia Niemann
RWRene H. Wijffels
Rene H. Wijffels
JMJens Matuszczyk
Jens Matuszczyk
Dirk MartensDirk Martens
Dirk Martens
Currently, the mammalian biomanufacturing industry explores process intensification (PI) to meet upcoming demands of biotherapeutics while keeping production flexible but, more importantly, as economic as possible. However, intensified processes often require more development time compared with conventional fed-batches (FBs) preventing their implementation. Hence, rapid and efficient, yet straightforward strategies for PI are needed. In this study we demonstrate such a strategy for the intensification of an N-stage FB by implementing N-1 perfusion cell culture and high inoculum cell densities resulting in a robust intensified FB (iFB). Furthermore, we show successful combination of such an iFB with the addition of productivity enhancers, which has not been reported so far. The conventional CHO cell FB process was step-wise improved and intensified rapidly in multi-parallel small-scale bioreactors using N-1 perfusion. The iFBs were performed in 15 and 250 mL bioreactors and allowed to evaluate the impact on key process indicators (KPI): the space-time yield (STY) was successfully doubled from 0.28 to 0.55 g∙(L∙d)-1, while product quality was maintained. This gain was generated by initially increasing the inoculation density, thus shrinking process time, and secondly supplementation with butyric acid (BA), which reduced cell growth and enhanced cell-specific productivity from ~25 to 37 pg∙(cell∙d)-1. Potential impacts of PI on cell metabolism were evaluated using flux balance analysis. Initial metabolic differences between the standard and intensified process were observed but disappeared quickly. This shows that PI can be achieved rapidly for new as well as existing processes without introducing sustained changes in cellular and metabolic behavior.

15 May 2023 in Current Opinion in Biotechnology
Verified
Journal Article
Open access
JMJens-Christoph Matuszczyk
Jens-Christoph Matuszczyk
GZGerben Zijlstra
Gerben Zijlstra
DEDavid Ede
David Ede
NGNavid Ghaffari
Navid Ghaffari
JYJoannes Yuh
Joannes Yuh
VBVeronica Brivio
Veronica Brivio
Two of the big challenges in modern bioprocesses are process economics and in-depth process understanding. Getting access to online process data helps to understand process dynamics and monitor critical process parameters (CPPs). This is an important part of the quality-by- design concept that was introduced to the pharmaceutical industry in the last decade. Raman spectroscopy has proven to be a versatile tool to allow noninvasive measurements and access to a broad spectrum of analytes. This information can then be used for enhanced process control strategies. This review article will focus on the latest applications of Raman spectroscopy in established protein production bioprocesses as well as show its potential for virus, cell therapy, and mRNA processes.

6 January 2021 in Engineering in Life Sciences
Verified
Journal Article
Open access
PDF file
KMKatharina V. Meyer
Katharina V. Meyer
ISIna G. Siller
Ina G. Siller
JSJana Schellenberg
Jana Schellenberg
ASAlina Gonzalez Salcedo
Alina Gonzalez Salcedo
DSDörte Solle
Dörte Solle
JBJanina Bahnemann
Janina Bahnemann
Due to the increasing economic and social relevance of biotherapeutics, their production processes are continually being reconsidered and reoptimized in an effort to secure higher product concentrations and qualities. Monitoring the productivity of cultured cells is therefore a critically important part of the cultivation process. Traditionally, this is achieved by determining the overall product titer by high performance liquid chromatography (HPLC), and then calculating the specific cell productivity based on this titer and an associated viable cell density. Unfortunately, this process is typically time‐consuming and laborious. In this study, the productivity of Chinese Hamster Ovary (CHO) cells expressing a monoclonal antibody was analyzed over the course of the cultivation process. In addition to calculating the specific cell productivity based on the traditional product titer determined by HPLC analysis, culture productivity of single cells was also analyzed via flow cytometry using a cold capture assay. The cold capture assay is a cell surface labelling technique described by Brezinsky et al., which allows for the visualization of a product on the surface of the producing cell. The cell productivity results obtained via HPLC and the results of cold capture assay remained in great accordance over the whole cultivation process. Accordingly, our study demonstrates that the cold capture assay offers an interesting, comparatively time‐effective, and potentially cheaper alternative for monitoring the productivity of a cell culture.